ESMO Interactive Guidelines vs SARCULATOR

The European Society for Medical Oncology (ESMO) guidelines are developed by experts. They are concise, practical and offer users treatment recommendations that are based on the latest scientific research. This application uses interactive tools to support decision making and help the user navigate the guidelines easily, so they can access the information they require quickly. Each guideline offers best practice recommendations for screening, diagnosis, staging, treatment and follow up. The ESMO Interactive Guidelines application ensures the user has the highest standard of information at their figure tips. A variety of interactive treatment algorithms, tables, calculators and scores can be utilised to assist the treating doctor. The user can also perform key word searches, bookmark useful pages, add notes and email pages to colleagues or patients. The app features news and push notifications. Disclaimer: The app is intended to assist healthcare professionals and allied healthcare professionals as an educational tool to provide information that may support them in providing care to patients. Patients or other community members using this app shall do so only after consultation with a health professional and shall not mistake these guidelines as professional medical advice. These guidelines must not substitute seeking professional medical and health advice from a health professional. These guidelines may not apply to all situations and shall be interpreted in the light of specific clinical situations and resource availability. It is up to every clinician to adapt these guidelines to local regulations and to each patient’s individual circumstances and needs. The app contains information obtained from authentic and highly regarded sources (http://www.esmo.org). Although every effort has been made to ensure that treatment and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician.This application is updated regularly with more tumour types, guidelines and interactive tools.

This app is meant to be used only by physicians and it is not meant to make clinical decisions (the clinical usefulness of the two models has not been tested) but to be used as an informative tool to improve the predictive capability of a physician. Two kinds of predictions are possible: - RPS: 5-year overall survival (OS) and 5-year disease-free survival (DFS) in primary resected retroperitoneal sarcoma (RPS) patients. . - ESTS: 5- and 10-year overall survival (OS) and cumulative incidence of distant metastasis (CCI of DM) in primary resected extremity STS patients.